VASERETIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vaseretic, and what generic alternatives are available?
Vaseretic is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in VASERETIC is enalapril maleate; hydrochlorothiazide. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the enalapril maleate; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vaseretic
A generic version of VASERETIC was approved as enalapril maleate; hydrochlorothiazide by TARO PHARM INDS on September 18th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VASERETIC?
- What are the global sales for VASERETIC?
- What is Average Wholesale Price for VASERETIC?
Summary for VASERETIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 134 |
| Patent Applications: | 3,164 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VASERETIC |
| What excipients (inactive ingredients) are in VASERETIC? | VASERETIC excipients list |
| DailyMed Link: | VASERETIC at DailyMed |
Pharmacology for VASERETIC
| Drug Class | Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
| Physiological Effect | Decreased Blood Pressure Increased Diuresis |
US Patents and Regulatory Information for VASERETIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | VASERETIC | enalapril maleate; hydrochlorothiazide | TABLET;ORAL | 019221-003 | Jul 12, 1995 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch | VASERETIC | enalapril maleate; hydrochlorothiazide | TABLET;ORAL | 019221-001 | Oct 31, 1986 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VASERETIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | VASERETIC | enalapril maleate; hydrochlorothiazide | TABLET;ORAL | 019221-003 | Jul 12, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | VASERETIC | enalapril maleate; hydrochlorothiazide | TABLET;ORAL | 019221-001 | Oct 31, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | VASERETIC | enalapril maleate; hydrochlorothiazide | TABLET;ORAL | 019221-001 | Oct 31, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | VASERETIC | enalapril maleate; hydrochlorothiazide | TABLET;ORAL | 019221-003 | Jul 12, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VASERETIC
See the table below for patents covering VASERETIC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | H02131496 | AMINO ACID DERIVATIVE AS ANTIHYPERTENSIVE AGENT | ⤷ Sign Up |
| Austria | 6503 | ⤷ Sign Up | |
| Norway | 151622 | ⤷ Sign Up | |
| European Patent Office | 0012401 | CARBOXYALKYL DIPEPTIDE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | ⤷ Sign Up |
| South Korea | 850000846 | ⤷ Sign Up | |
| South Africa | 7906688 | ⤷ Sign Up | |
| Israel | 58849 | CARBOXYALKYL DIPEPTIDES AND DERIVATIVES THEREOF,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
